GILD241115C40000
- 24.47
- 0.000.00%
Gilead Sciences Newsroom
Shares of Pharmaceutical and Healthcare Stocks Are Trading Lower. The Sector Has Been Under Pressure After President-elect Trump Nominated Robert F. Kennedy Jr. to Lead the HHS.
Large Pharmas, Biotechs Down as Industries Grapple With RFK Jr. at HHS
U.S. Pharma Is Largely Immune From 'MAHA' Impact: Wolfe
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead on Pace for Largest Percent Decrease Since February -- Data Talk
Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response
Express News | Biotechnology etf plunges! Pharmaceutical stocks collectively decline, with the United States Secretary of Health and Human Services nominee raising market concerns.
Express News | Gilead Sciences Inc - No Treatment-Related Serious Adverse Events Reported for Livdelzi
Express News | Gilead Sciences Inc - Livdelzi Shows 81% Efficacy in Phase 3 Assure Study
Express News | Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences Initiated at Outperform by Wolfe Research
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
Wolfe Research Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $110
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Gilead Sciences, Inc. (GILD) Is Attracting Investor Attention: Here Is What You Should Know
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Today's Analyst Rating | NVIDIA Price Target Raised to $175 by Oppenheimer, Amazon Price Target Raised to $250 by Needham
Nov 14, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Amazon(AMZN.US)$.
Gilead Sciences Analyst Ratings
Gilead Sciences (GILD) Gets a Buy From TD Cowen
The application for the long-acting HIV therapy by Gilead (GILD.US) is about to be submitted.
Gilead Sciences (GILD.US) today announced the full results of the second pivotal Phase 3 trial PURPOSE 2 for lenacapavir, an investigational long-acting HIV-1 capsid inhibitor administered once every six months for HIV prevention.